ISRGNASDAQ— Intuitive Surgical Inc Price & Analysis

Intuitive Surgical Inc

HEALTHCARE — MEDICAL INSTRUMENTS & SUPPLIES

$366.70

-$3.13-0.85%

Market Cap: $132.50B; Large Cap
P/E Ratio: 42.75; Fwd: 30.4
EPS (TTM): $8.65
Div. Yield: N/A

Technical Summary

RSI (14)43.02Neutral

SMA (50)$381.01Bearish

SMA (200)$463.81Bearish

MACD-3.4970Bearish

Bollinger$356.58 – $406.84Mid

Stochastic11.97Oversold

Theo Outlook

Intuitive Surgical (ISRG) presents a bullish thesis with a $131.4B market cap, trailing P/E of 42, EPS of $8.73, and 18.5% YoY quarterly revenue growth to $11.0B TTM, supported by 28.4% profit margins and 17.4% ROE. The stock trades at a premium reflecting its dominant position in robotic-assisted surgery, with forward P/E of 30.5 and analyst target of $478 implying upside from current levels near the 50-day moving average of $381. Key catalysts include continued adoption of the da Vinci Surgical System, expansion into new surgical procedures and international markets, and strong earnings momentum with 26.5% YoY quarterly EPS growth. Product innovation in minimally invasive technologies and rising procedure volumes drive recurring revenue from instruments and services, positioning ISRG for sustained double-digit growth. Risks include regulatory hurdles from FDA approvals for new systems, intensifying competition from emerging robotic platforms, and macro headwinds such as hospital capital spending constraints amid higher interest rates. Mitigations involve ISRG's extensive clinical data moat, diversified global footprint, and robust balance sheet enabling R&D investment to maintain technological leadership. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Analysis generated by HeyTheo AI on Sep 7, 2026.

Company Overview

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Fundamental Snapshot

Revenue: $11.03B
EBITDA: $4.18B
Gross Profit: $7.36B
Operating Margin: 33.6%
Profit Margin: 28.4%
ROE: 17.4%
Book Value: $51.34
Beta: 1.46
52-Wk High: $603.88
52-Wk Low: $328.57
Avg Volume: 2.08M
PEG Ratio: 1.61

Frequently Asked Questions

What is Intuitive Surgical's business model?

Intuitive Surgical develops, manufactures, and markets robotic surgical systems, primarily the da Vinci platform, generating revenue from system sales, recurring instrument and accessory sales, and service contracts. With $11.0B TTM revenue and 28.4% profit margins, the model emphasizes high-margin recurring revenue from procedures performed on installed systems.

What are ISRG's main revenue sources?

Revenue comes from da Vinci system sales, instruments and accessories (the largest and highest-margin segment), and services. TTM revenue reached $11.0B with 18.5% YoY growth, driven by increasing procedure volumes and system placements worldwide.

What are ISRG's key competitive advantages?

ISRG holds a dominant market position with over 8,000 da Vinci systems installed, backed by extensive clinical data, surgeon training programs, and a large installed base creating switching costs. Its 42x trailing P/E reflects this moat, with 17.4% ROE and strong analyst ratings (7 strong buy, 17 buy).

What are the main risks for ISRG stock?

Key risks include regulatory delays for new products, competition from other robotic surgery firms, and sensitivity to hospital capital budgets. The stock's 1.465 beta indicates higher volatility, with a 52-week range of $328.57-$603.88 reflecting macro and sector pressures.

What is the growth outlook for ISRG?

ISRG shows strong growth potential with 18.5% revenue growth, 26.5% EPS growth, and an analyst target price of $478. Expansion in new indications, international markets, and next-generation systems support continued double-digit growth, though the 42x P/E prices in much of this optimism.